Ablynx and Procter & Gamble extend Nanobody drug discovery development agreement to metabolic targets
11-Apr-2006 -
Ablynx has announced that its drug discovery and development alliance with Procter & Gamble Pharmaceuticals, Inc. (P&GP), a subsidiary of The Procter & Gamble Company, has been extended to include metabolic disease targets. Through this agreement, Ablynx will use its unique and patent protected ...
Ablynx
metabolic diseases
milestone payments